An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease

Trial Profile

An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Carfilzomib (Primary)
  • Indications Multiple myeloma
  • Focus Pharmacokinetics
  • Sponsors Onyx Pharmaceuticals
  • Most Recent Events

    • 01 Jun 2017 Results published in the Cancer Chemotherapy and Pharmacology.
    • 20 Dec 2016 Planned End Date changed from 1 Oct 2016 to 1 Apr 2017.
    • 07 Dec 2016 Results of a population pharmacokinetic model analysis and exposure response analysis based on pooled data from PX171-003, PX171-004, PX171-005, PX171-006, PX171-007, ASPIRE, ENDEAVOR, CFZ001 and CFZ002 studies published in the Journal of Clinical Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top